AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Plus Therapeutics Granted Continued Nasdaq Listing with Conditions
ByAinvest
Wednesday, Aug 13, 2025 9:35 pm ET1min read
Plus Therapeutics (PSTV) has been granted continued Nasdaq listing after failing to meet the minimum stockholders' equity requirement of $2.5 million. The company must meet specific conditions by August 14 and September 8, 2025, to maintain its listing. Analysts rate PSTV a buy with a $8.00 price target, but the stock faces significant financial challenges with negative equity and ongoing losses.
Plus Therapeutics Inc. (NASDAQ: PSTV), a biotechnology company focused on developing innovative therapeutic solutions, has been granted a continued listing on the Nasdaq Stock Market after failing to meet the minimum stockholders' equity requirement of $2.5 million. The company must adhere to specific conditions set by the Nasdaq Stock Market to maintain its listing, including meeting certain financial thresholds by August 14 and September 8, 2025 [1].The company recently announced that it filed a prospectus for the sale of 33 million shares of common stock by the selling stockholder. This move is part of Plus Therapeutics' strategy to bolster its financial position and ensure compliance with Nasdaq's listing requirements [1].
Analysts have a positive outlook on Plus Therapeutics, with a majority rating the stock as a "buy" and a median 12-month price target of $8.00. However, the company faces significant financial challenges, including negative equity and ongoing losses. In its latest earnings report, Plus Therapeutics is expected to post a loss of 9 cents per share, with revenue projected to rise by 16.2% to $1.486 million for the quarter ending June 30, 2025 [2].
Despite these challenges, the company's stock has shown resilience, with analysts expecting it to rebound. Plus Therapeutics' historical earnings data indicate a mixed performance, with some quarters showing significant beats and others missing estimates [2]. The company's ability to navigate these challenges and meet the required conditions will be crucial in determining its long-term success.
References:
[1] https://seekingalpha.com/news/4484250-plus-therapeutics-files-to-sell-33m-shares-of-common-stock-for-holders
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U01X6:0-plus-therapeutics-inc-expected-to-post-a-loss-of-9-cents-a-share-earnings-preview/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet